Avlon Pharma forecasts 800M riyals from Terzipatide

Avlon Pharma expects the Terzepatide drug to generate revenues of no less than 800 million SAR during the first five years of its launch in the target markets of the Middle East and North Africa. The drug's revenues are estimated to account for less than 5% of the company's annual revenue according to the 2025 forecasts. This aligns with the company's strategy to strengthen its portfolio and expand its presence in diabetes and metabolic treatments. An exclusive licensing agreement has been signed to enable the registration and marketing of the drug at various concentrations using multi-dose pen technology, with the possibility of transferring manufacturing technology.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل